Affilogic,a member of Atlanpole Biotherapies, has received a € 5000 voucher as part of the Boost4Health programme. This support has... View Article
Author Archives for Adeline Chauvigné
Affilogic is financing a proof of concept thanks to the Boost4Health programme
30 June 2025Affilogic,a member of Atlanpole Biotherapies, has received a € 5000 voucher as part of the Boost4Health programme. This support has... View Article
A thymic cell study programme for developing an ambitious transplant strategy
This programme is led by Dr. Matthieu Giraud, a specialist in immunology, genetics and bioinformatics. Having spent a number of... View Article
A thymic cell study programme for developing an ambitious transplant strategy
30 June 2025This programme is led by Dr. Matthieu Giraud, a specialist in immunology, genetics and bioinformatics. Having spent a number of... View Article
In-Cell-Art announces a contract with one of top 5 Global Pharmas to discover potential antibodies medicines
Nantes – France, 24 of May , 2018 – In-Cell-Art (ICA), a member of Atlanpole Biotherapies, a biotechnology company specialized in... View Article
In-Cell-Art announces a contract with one of top 5 Global Pharmas to discover potential antibodies medicines
30 June 2025Nantes – France, 24 of May , 2018 – In-Cell-Art (ICA), a member of Atlanpole Biotherapies, a biotechnology company specialized in... View Article
Hemarina announces positive preclinical proof of concept results on lung preservation before transplantation
Hemarina, a member of Atlanpole Biotherapies, the marine biotechnology company specializing in the development of extracellular universal oxygen carriers for unmet... View Article
Hemarina announces positive preclinical proof of concept results on lung preservation before transplantation
30 June 2025Hemarina, a member of Atlanpole Biotherapies, the marine biotechnology company specializing in the development of extracellular universal oxygen carriers for unmet... View Article
HORAMA Appoints Dr Russell Greig as New Chairman of the Board
Paris, May 15, 2018 – Horama, a French biotech company based in Paris and Nantes, is a spin-off of Philippe... View Article
HORAMA Appoints Dr Russell Greig as New Chairman of the Board
30 June 2025Paris, May 15, 2018 – Horama, a French biotech company based in Paris and Nantes, is a spin-off of Philippe... View Article
OSE Immunotherapeutics receives the Euronext Tech 40 Label
Nantes, France, April 23 2018, OSE Immunotherapeutics, a member of Atlanpole Biotherapies, has received the Euronext Tech 40 Label and... View Article
OSE Immunotherapeutics receives the Euronext Tech 40 Label
30 June 2025Nantes, France, April 23 2018, OSE Immunotherapeutics, a member of Atlanpole Biotherapies, has received the Euronext Tech 40 Label and... View Article
InFlectis BioScience IFB-088 enters phase-1 clinical trial
InFlectis BioScience SAS, a member of Atlanpole Biotherapies, a drug discovery company committed to the development of innovative therapeutics harnessing... View Article
InFlectis BioScience IFB-088 enters phase-1 clinical trial
30 June 2025InFlectis BioScience SAS, a member of Atlanpole Biotherapies, a drug discovery company committed to the development of innovative therapeutics harnessing... View Article
Florence Hallouin joins the CEBR’s board
Atlanpole Biotherapies and CEBR The Annual CEBR (Council of European BioRegions) meeting was held from 22 to 23 March in... View Article
Florence Hallouin joins the CEBR’s board
30 June 2025Atlanpole Biotherapies and CEBR The Annual CEBR (Council of European BioRegions) meeting was held from 22 to 23 March in... View Article
Franck Grimaud elected president of Atlanpole Biotherapies cluster
On 20 February 2018, Franck Grimaud, managing director of Valneva since 1999, was elected chairman of the Atlanpole Biotherapies western... View Article
Franck Grimaud elected president of Atlanpole Biotherapies cluster
30 June 2025On 20 February 2018, Franck Grimaud, managing director of Valneva since 1999, was elected chairman of the Atlanpole Biotherapies western... View Article
Atlanpole Biotherapies presents its strategic priorities
At its annual meeting , the Atlanpole Biotherapies western France biocluster presented its 2017 business report and outlook for 2018.... View Article
Atlanpole Biotherapies presents its strategic priorities
30 June 2025At its annual meeting , the Atlanpole Biotherapies western France biocluster presented its 2017 business report and outlook for 2018.... View Article